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People who inject drugs are more likely to be HIV positive and to have a mental disorder than the general population. We explore
how the detection and treatment of mental illness among people who are injecting drugs are essential to primary and secondary
prevention of HIV infection in this population. Aside from opioid addiction, few studies have been conducted on the links between
mental disorders and injection-drug use. However, independent of the injection-drug use literature, a growing number of studies
demonstrate that untreatedmental illness, especially depression and alcohol/substance use disorders, is associatedwithHIV-related
risk behaviors, acquiring HIV infection, failure to access HIV care and treatment, failure to adhere to HIV care and treatment, and
increased morbidity and mortality from HIV-related diseases and comorbidities. In our review of both the published literature
and gray literature we found a dearth of information on models for providing care for both opioid addiction and other mental
illnesses regardless of HIV status, particularly in low- and middle-income countries. We therefore make recommendations on how
to address the mental health needs of HIV-positive people who inject drugs, which include the provision of opioid substitution
therapy and integrated mental health, substance abuse, and HIV services.
1. Introduction
eHIV epidemic is intertwined with many other epidemics
such as hepatitis C and tuberculosis and, just as powerfully,
with substance use disorders and other mental illnesses.
roughout the world, HIV begins its spread among three
vulnerable populations with high rates of mental disorders:
people who inject drugs (PWID), men who have sex with
men (MSM) and sex workers [1]. Following infection, the
presence of HIV in the brain, HIV-related central nervous
system and systemic complications, and the side effects of
antiretroviral medications cause their own neuropsychiatric
complications, further complicating this picture.
While in many treatment settings and government agen-
cies substance use and other mental illnesses have been
separated, this separation has created barriers to holistic
care because there is considerable comorbidity between these
two sets of disorders with nonaddictive mental disorders
oen preceding substance use disorders [2]. Data shows that
among individuals with a lifetime history of substance abuse,
over half were also affected by another mental disorder [3].
Conversely, individuals with nonaddictive mental disorders
are more likely to have substance-use disorders than the
general population.One survey found that 24% of individuals
with lifetime major depressive disorder also had a substance-
use disorder [3]. In a US national comorbidity study,
aggregate analyses demonstrated signi�cant prospective risks
posed by baseline mental disorders for the onset of nicotine,
alcohol and illicit drug dependence with abuse over the
follow-up period [2].
is paper is focused on the key population of people
who inject drugs keeping in mind that people engaging in
injection-drug use overlap with both MSM and sex workers.
We explore how the detection and treatment of mental
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illness among people who are injecting drugs are essential
to primary and secondary prevention of HIV infection in
this population. e term mental disorders will be used in
this paper in a manner that is consistent with the Diagnostic
and Statistical Manual of Mental Disorders Fourth Edition
(DSM-IV) of the American Psychiatric Association [4].
Aside from opioid addiction, few studies have been con-
ducted on the links between mental disorders and injection-
drug use. However, independent of the injection-drug use
literature, a growing number of studies demonstrate that
untreated mental illness, especially depression and alco-
hol/substance use disorders, is associated with HIV-related
risk behaviors, acquisition of HIV infection, failure to access
HIV care and treatment, failure to adhere to HIV care
and treatment, and increased morbidity and mortality from
HIV-related diseases and comorbidities [5, 6]. In addition,
with an increased focus on antiretroviral treatment (ART)
as a strategy for primary and secondary HIV prevention,
addressing mental disorders that interfere with regularly tak-
ing HIV medications is essential to treatment as prevention
efforts.
Studies not only show the negative impact of mental
disorders on HIV/AIDS, but also the positive impact of
mental health treatment for mental disorders. For example,
several studies have shown that antidepressant treatment
is associated with improved adherence to antiretrovirals in
HIV-positive individuals with depression [7, 8].
Yet the treatment of mental disorders remains a highly
underfunded component of HIV prevention, care and treat-
ment, even in many high-income countries. If treatment as
prevention is to be effective, we must do better at identify-
ing people who have HIV infection, linking them to care,
retaining them in care, initiating antiretroviral treatment
and achieving adherence that results in suppressed viral
load. For example, the CDC approximates that the U.S.
has an estimated 1.2 million persons of whom about 80%
know that they are infected [9]. Of those who knew their
status about three quarters were linked to care and half
remained in care. Among all HIV-infected persons in the
United States the CDC has estimated that only 28% are on
antiretroviral treatment and have a suppressed viral load. We
know that mental disorders have a negative impact at each
step in the cascade of HIV testing, care, and treatment. We
argue that the time has come to identify and treat mental
disorders as an integral part of HIV prevention strategies for
people who inject drugs and other overlapping vulnerable
populations.
2. Epidemiology of HIV and Access and
Adherence toHIVCare andTreatment among
PeopleWho Inject Drugs
People who inject drugs are becoming more important in the
global landscape ofHIV/AIDS because PWID are accounting
for a larger proportion of new cases of HIV infection [10].
Injection-drug use has been identi�ed in 148 countries with
the largest numbers of injectors identi�ed in China, the
United States, and Russia [11].
Data on the extent of injection-drug use is absent for
many countries in Africa, the Middle East, and Latin Amer-
ica. Africa, the continent with the largest HIV epidemic,
has had an increasing role in global drug trafficking routes,
leading to increasing injection-drug use transmission of HIV
[12].is is especially true inNigeria, Kenya, Tanzania, South
Africa, and Mauritius. Kenya alone had 7% of its new HIV
infections attributable to drug injection in 2008, and 42% of
Kenya’s PWID population are HIV infected [12].
It is estimated that outside of sub-Saharan Africa, one
in three new HIV cases is attributed to injection-drug use
[10]. And in parts of the world where the epidemic is
growing rapidly, such as Eastern Europe and Central Asia,
some estimates show more than 80% of HIV transmission
occurring among PWID [10]. People who inject drugs are
more likely to be HIV positive than the general population.
Estimates vary widely on the prevalence of HIV among
PWID; however a 2008 systematic review suggests that the
average global prevalence rate of HIV among PWID is 18%
[8], compared to 0.8% of the general population [13].
In recent years HIV prevention efforts have increasingly
incorporated the concept of treatment as prevention in
response to a growing understanding that antiretroviral treat-
ment can protect HIV-negative people from acquiring HIV
and HIV-positive people from transmitting HIV. Because
people who inject drugs play such a central role in the
acquisition and transmission of HIV infection through risky
sexual and drug use practices, it is very important for PWID
to have access to and adhere to antiretroviral treatment.
However, multiple studies have shown that even in settings
where ART is widely available, people who inject drugs are
less likely to start ART than other HIV-positive populations
[3, 13]. Studies have found that PWID commonly present for
HIV treatment later in the stage of the disease when AIDS
symptoms are present. Later HIV-stage initiation of ART
predicts worse prognosis and survival outcomes [3] and, as
already noted, poses a greater likelihood of HIV transmission
to others. PWID have also been found to be less adherent to
antiretroviral treatment than other HIV positive populations
[3, 14] and are more likely to discontinue ART treatment
outright aer it has been started [14].
3. Epidemiology of Mental Disorders among
PeopleWho Inject Drugs
e literature onmental illness among people injecting drugs
is limited. e presence of substance use disorders among
PWID is the most obvious link between psychiatric illness
and injection-drug use. In the USA and elsewhere, the most
commonly injected drugs are opioids and stimulants [15].
While injection of these substances could be an intermittent
behavior that is not occurring in the context of addiction,
studies of current and former people who injected drugs
have found that the vast majority of them suffer from one
or more addictive disorders; they are polydrug users, using
both injected and noninjected substances, including alcohol.
In addition, the presence of nonaddictive mental disorders
was much higher than that seen in the general population.
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While not focused on speci�c mental disorders, one
study in Australia measured the self-reported wellbeing of
the PWID participants using the Personal Wellbeing Index
(PWI) and found that PWID had profoundly lower scores
than the general Australian population [16]. A review of
psychiatric comorbidity among people who inject drugs in
Africa and Asia found that psychological distress was high,
including suicidal ideation and attempts [17].
A team in Chicago [18] used various outreach techniques
to gather mental health information on 570 young and
mostly white PWID who were not currently in treatment
and who had injected less than one month ago. About 98%
of subjects met criteria for opioid dependence. Rates of
alcohol, cannabis and cocaine abuse and dependence among
male and female subjects varied between 14%–21%. Lifetime
prevalence for other mental illnesses was much higher than
in the general population and differed by gender: primary
major depression: men 9%, women 21%; substance-induced
major depression: men 22%, women 35%; posttraumatic
stress disorder (PTSD): men 6%, women 17%; any primary
anxiety disorder: men 13%, women 30%; antisocial person-
ality disorder: men 30%, women 23%; borderline personality
disorder: men 19%, women 28%.
It can be difficult to distinguish between psychiatric
syndromes induced by drug intoxication/withdrawal from
those that are independent of drug use. Brooner et al.
attempted to do this by assessing 716 opioid abusers in
Baltimore, Maryland aer they had been stabilized on
methadone maintenance [19]. Using the Structured Clinical
Interview for DSM-III-R [20], the authors found that 24%
of subjects met lifetime criteria for an Axis-I nonsubstance
psychiatric disorder, most commonly major depression. On
Axis-II, 35% had a personality disorder, most commonly
antisocial personality disorder. At the time of entry into
treatment 100% of subjects met criteria for current opioid
dependence. In addition, lifetime rates of drug dependence
with other substanceswere as follows: cocaine, 65%; cannabis,
51%; alcohol, 50%; sedatives, 45%; stimulants, 19%; and
hallucinogens, 18%.
Other studies in theUSAandTaiwanunderscore thewell-
established �nding that the vast majority of people who inject
drugs suffer from addictive disorders [21, 22].
e type of drug addiction affects the degree of HIV risk
that drug injection poses. For example, to maintain a high,
individuals injecting cocaine, which is rapidly metabolized,
must inject much more frequently than those using longer
acting drugs like opioids; therefore obtaining new needles for
each injection can become difficult [15].
Nonaddictive mental illnesses can also increase unsafe
injection-drug use practices. In a study of 343 opioid-
dependent adults recruited from 12 sites across the United
States and enrolled in multisite studies of the National
Drug Abuse Treatment Clinical Trials Network (CTN001-
002), depressive symptoms were associated with an increased
level of injection risk behaviors [23]. Past suicide attempts
were associated with a history of drug injection among
almost 7,000 Swedish criminal justice clients with suspected
substance-related problems [24].
Although not speci�c to injection-drug use, the US
national comorbidity study (NCS) of 5,000 people inter-
viewed at two time points about a decade apart provides
evidence that strongly suggests nonaddictive mental dis-
orders oen precede addictive disorders [2]. Among par-
ticipants who had never used illicit drugs before, having
any sort of psychiatric disorder almost tripled the risk for
eventually using, abusing, or becoming dependent on illicit
substances, and the greater number of psychiatric disorders
the greater the risk. With regard to speci�c disorders and
the risk of developing a future substance use disorder,
major depression was associated with twice the risk; panic
disorder, intermittent explosive disorder and oppositional
de�ant disorderwith three times the risk; and attention de�cit
hyperactivity disorder and separation anxiety with about a
fourfold increase in risk.e authors state “retrospective and
prospective studies both indicate thatmental disorders have a
temporally primary age of onset in themajority of these forms
of comorbidity”.
In summary, nonaddictive mental disorders oen pre-
cede addictive disorders and both contribute to the risk of
acquiring and transmitting HIV among people at risk for or
currently injecting drugs, including high-risk sex, non-help-
seeking behaviors, and nonadherence to ART.
4. Overlap between Injection-Drug Use,
SexWork, andMental Illness
Injection-drug use and commercial sex work are strongly
linked. Examining this link is helpful for two reasons: risky
sexual behavior is an important route of HIV transmission
from PWID to the general population and there is a larger
literature on mental illness among sex workers than there is
among those who inject drugs.
Commercial sex work is an economic exchange in which
speci�c sexual activities are purchased or traded for other
goods. Many social and economic factors are associated
with sex work, including extreme poverty, illiteracy, and
unaddressed (or even sanctioned) violence, especially against
men who have sex with men and women.ese factors are in
turn associated with poor mental health. Multiple studies of
sex workers, including female, male, and transgendered sex
workers, have shown that this is a population with high rates
of both addictive and nonaddictive mental disorders, as well
as high rates of HIV-related risk behaviors.
In a study in St. Petersburg (Russia), 81% of surveyed sex
workers said they injected drugs at least once a day, 65% of
those injecting had used nonsterile injecting equipment, and
48% of sex workers were HIV-positive [25]. Similar rates of
HIV infection were reported among female sex workers who
inject drugs in Ho Chi Minh City (Viet Nam) [25]. Among
men who inject drugs in Viet Nam, having contacts with
female sex workers was associated with a greater likelihood
of being HIV positive [26]. Illegal drug use, particularly with
injection drugs, was the single greatest risk factor for HIV
infection among female sex workers in Kaiyuan City, China
[27].
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A study in Zanzibar looked at 509 men who have sex
with men (MSM) living in the community of whom 66 also
injected drugs [28]. MSM-PWID were twice as likely to have
HIV infection as non-PWIDMSM.ey were also �ve times
less likely to wear a condom with a paid female partner and
ten times less likely with a nonpaid female partner. MSM-
PWID were much more likely to have engaged in group sex
with other men in the past month. ey also reported poor
needle habits with a majority indicating that they used a
needle aer someone else and had passed around a needle
aer using it themselves. is study demonstrates that while
MSM are at high risk of HIV acquisition and transmission,
those who are also injecting drugs are at even higher risk,
in part through unsafe drug injection practices and in part
through links to commercial sex work and other risky sexual
practices.
Transition to injection-drug use was associated with
involvement in sex work amongAboriginal people in Canada
[29], and in another Canadian study, this time of HIV-
infected PWID who had achieved viral suppression on ART,
sex-trade involvement was associated with viral rebound
[30].
A study in Puerto Rico found that 47% of female sex
workers injected drugs [31]. In this study sex workers with
high levels of depressive symptoms had a 70%HIV infection
rate, whereas those with low depressive symptoms had a 30%
infection rate. is did not appear to be a consequence of
HIV infection, since depressive symptoms were independent
of HIV status.
Childhood sexual and physical abuse histories are
common among male and female sex workers [32–35].
Moreover, throughout the world, including Australia, South
Africa, ailand, Turkey, the United States, and Zambia, sex
workers report being raped and physically assaulted during
the course of their work. ese childhood and adult traumas
are associated with signi�cant suicidal ideation and risk, and
high rates of mental disorders, especially depression and
PTSD [16, 32–40].
Roxburgh et al. studied 72 female street-based sex work-
ers in Australia. More than 80% were heroin dependent
and injecting drugs [35]. About half of these sex workers
had begun injecting drugs prior to sex work and used sex
work to pay for their drugs. Half of the women reported
using drugs to facilitate their sex work largely through their
numbing effects. Among these women, 47% met a lifetime
DSM-IV diagnosis of posttraumatic stress disorder. What
emerged was a complex intertwinement of childhood abuse
and neglect, PTSD, symptoms of depression, injection drug
use, and engaging in sex work.
Vanwesenbeeck [41] conducted an exhaustive review of
the research literature on sex workers from 1990 through
2000 and concluded that in the Western world, injection
drug use and noncommercial sexual activity are the most
important risk factors for HIV infection in female sex
workers. is is similar to the �ndings of �ilchrist et al. [42]
who studied 118 women who inject drugs in Barcelona and
found that coercion into sex and sex exchange were common.
However, noncommercial partners had a stronger in�uence
on risky behaviors, needle sharing, and unprotected sex than
did male clients.
5. Mental Disorders as Risk Factors for
Injection-Drug Use
Mental disorders oen precede the onset of injection-drug
use. Again, the most obvious link is to current addictive
disorders as already described above. In addition, studies
show that early onset of alcohol and polysubstance use is an
important risk factor for injecting drugs in adulthood [43].
Injection-drug use has been found to be a risk factor for
HIV among people with severe mental illness. Meade and
Sikkema [44] did a literature review of this link and found 17
studies demonstrating an average rate of ever injecting drugs
of 22%, and a past year rate of 4%. Of these studies, eight
looked at needle sharing and found on average 61% lifetime
and 50% past year rates of this behavior.
6. Need for Mental Health Services for
People Living with HIV/AIDS
e need for mental health services for people living with
HIV/AIDS (PLWHA) is clear. Mental illness has been shown
to impact HIV transmission as well as disease progression
[45]. Depression, substance use disorders, and other severe
mental illnesses are associated with transmission risk behav-
iors such as risky sexual activity and drug injection among
both HIV-negative and HIV-positive people [46]. In terms
of disease progression, poor mental health in general, and
depression and substance use in particular, have been shown
to negatively affect antiretroviral therapy adherence, which
can cause poorer health outcomes and increased risk for HIV
transmission [47, 48].
People who have been diagnosed with severe mental
illnesses have a higher prevalence of HIV than the general
population [49]. One study found individuals with serious
mental illnesses 8 times more likely to be HIV positive than
the general population [8]. Conversely, PLWHA have higher
rates of mental disorders [14], particularly depression [50],
with HIV-positive individuals nearly twice as likely to be
diagnosed with major depression as HIV-negative individ-
uals [50]. Depression is the most common mental disorder
among HIV-infected people and is present in 30–50% of
patients in HIV care and treatment settings [48]. Studies have
found that chronic depressive symptoms are associated with
a higher risk of mortality, particularly for women living with
HIV, who are twice as likely to die as HIV-infected women
with limited or no depressive symptoms [51, 52]. ere is
also evidence that psychological distress can shorten the time
from HIV to AIDS, particularly among PWID [53].
7. Recommendations forMentalHealth Services
for People Living with HIV/AIDS
ere are a variety of guidelines for addressing mental
disorders among people with HIV/AIDS. We have chosen
to present guidelines developed by the US Agency for
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International Development (USAID) because USAID has
a global focus and has been very involved, particularly
in their collaboration with the US Office of the Global
AIDS Coordinator, in supporting the care of people with
HIV/AIDS.
Support and Technical Assistance Resources (AIDSTAR-
One) through USAID produced a technical brie�ng in �009
on the mental health needs of people living with HIV/AIDS
who suffer from mental health or substance use disorders
[54]. ey break down the continuum of HIV/AIDS into
three phases: pre-ART, ART, and the advanced disease/end-
of-life phase. Even as the pre-ART phase becomes briefer
and in some countries disappears as patients who test HIV
positive are offered immediate ART, the AIDSTAR-One
recommendations remain relevant.
7.1. Pre-ART Phase. During the pre-ART phase of HIV/
AIDS, PLWHA have �ve distinct mental health needs.
Firstly, it is essential that PLWHA receive early screening
for and diagnoses of mental health and substance use
disorders. e mental disorders that are associated with HIV
include adjustment disorders, mood disorders including
major depression, anxiety disorders including panic
disorder and posttraumatic stress disorder, substance use
disorders, HIV-associated dementia (also known as AIDS
dementia complex), and milder neurocognitive impairment.
Treatment of co-occurring disorders can lead to improved
HIV-related health outcomes and reduce transmission
risk.
Secondly, PLWHA with a substance use or other mental
disorder must have access to HIV care and treatment.
PLWHA with co-occurring mental disorders are less likely
to start and remain on ART treatment. irdly, when a
person living with HIV/AIDS is �rst diagnosed, there are
speci�c mental health needs that arise in response to the HIV
diagnosis. HIV diagnosis can trigger concerns over death,
stigma of the disease, changes in personal relationships,
and uncertainty of the future. ese concerns can trigger
anxiety or depression and both can have a negative impact
on accessing ART treatment or remaining in treatment.
Fourthly, there are very speci�c mental health needs for
PLWHA around stigma and discrimination as a result of
being HIV positive. e consequences of HIV stigma can
include social isolation, marginalization and discrimination
and can directly impact a person’s care-seeking behaviors.
Finally, because HIV infection is a chronic illness, PLWHA
are in need of ongoing psychosocial support. Psychosocial
support can help reduce the psychological distress of living
with HIV and also improve ART adherence and disease
outcomes.
7.2. Antiretroviral Treatment Phase. During the ART phase,
many of the mental health needs from the pre-ART phase
are still relevant, particularly those dealing with stigma,
access to care, emotional response, and psychosocial support.
However there are certain mental health needs that are
speci�c to the ART phase of HIV/AIDS in people with
co-occurring disorders. ese include adherence to ART,
management of mental and substance use disorders, and side
effects and cognitive impairments as a result of HIV itself and
its treatment.
7.3. Advanced Disease/End-of-Life Phase. Despite the fact
that effective treatment exists forHIV,many deaths still occur
as a result of HIV infection. If a person living with AIDS
progresses to very advanced stages of the disease where death
is likely, mental health needs are particularly important in
caring for that person and his or her caregivers. Both the
patient and the caregivers will need substantive physical,
emotional and spiritual support as they go through the
process of death and dying, as well as grief and loss. ese
support systems can be both formal and informal.
8. Models for and Barriers toMental Health
Services for People Living with HIV/AIDS
It is currently not possible to carry outmost of the AIDSTAR-
One recommendations in most parts of the world, and the
vast majority of people who inject drugs are not in treatment
for their addictive or nonaddictive mental illnesses. While
mental disorders are common, accounting for 13% of the
total global burden of disease, adequate treatment is oen not
available [14]. In high-income countries, there is a 35–50%
treatment gap for mental disorders. In low- and middle-
income countries the gap is even more pronounced, with
between 76–85% of those in need of services not receiving
treatment for mental disorders [14]. Low- and middle-
income countries have not only the largest treatment gap for
mental disorders, but also the highest burden of HIV/AIDS,
with sub-Saharan Africa alone accounting for 69% of the
entire population of people living with HIV/AIDS [55]. Still
another barrier to treatment is that drug use disorders are
oen criminalized rather than treated [56]. With the clear
association betweenmental disorders andHIV/AIDS and the
enormous gap in mental health treatment services, especially
in low- and middle-income countries, there is an obvious
need for improved HIV and mental health interventions.
In addition, virtually every funding stream for people
with HIV/AIDS spends very little money on the treatment
of mental disorders. Factors that explain this include the lack
of recognition and the stigma of mental illnesses and the
low priority given to these disorders by country leadership
(both public and private), including in the USA, and by the
HIV experts and scientists who drive the HIV treatment and
research agenda. ey may share a common misperception
that mental health services are costly, derived from basing
their estimates on per capita costs of psychiatric care, even
though many services are now provided by community
workers through an approach called task-shiing [57].
Another concern in relation to the speci�c needs of
people who inject drugs is the availability and legality of
opioid substitution therapy (OST). Of the �ve countries that
have megaepidemics of HIV among PWID—Russia, China,
Ukraine, Vietnam, and Malaysia—OST is available in all but
Russia. In Russia, methadone and buprenorphine remain
illegal for use in addiction treatment [58]. However, even in
those countries where opioid substitution therapy is legal,
OST is offered to less than 5% of patients that are in need
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of drug treatment. While these percentages are very low,
they are on the rise and countries, particularly those with
megaepidemics, with the exception of Russia, are increasing
the number of people receiving OST [58].
In high-income countries, OST is generally more avail-
able. By 2000, all but two European Union countries (Cyprus
and Estonia) had introduced opioid substitution therapy,
providing drug treatment for approximately one third of
the PWID. It is estimated that between 1998 and 2004,
15% to 25% of addicted opioid users were receiving opioid
substitution therapy [59].
While availability of OST is oen the �rst step to treating
PWID, maintaining drug treatment is also important. In the
Mackesy-Amiti et al. [18] US-based study of PWID, while
68% had received some form of substance abuse treatment in
the past, only 5% were currently in treatment and only 10%
reported current 12-step program attendance.
Beyond the treatment of opioid addiction with OST and
the provision of clean injection equipment, it is difficult to
identify effective and tested treatment models for HIV posi-
tive PWID with the common psychiatric comorbidities that
we have discussed. Our own search through the Columbia
University Libraries article database and PubMed revealed
a dearth of peer-reviewed articles on models for providing
care for both opioid addiction and other mental illnesses
regardless of HIV status. Rarer still are articles that concern
non-Western countries, as other reviewers have noted [17].
Even fairly comprehensive articles on the subject of illicit
drugs and HIV treatment seem to handle mental illness
as merely another comorbidity that includes its own set
of prescription drugs with speci�c interactions, rather than
addressing the absence of systems to deliver mental health
care [60].
We therefore also searched the gray literature in the hopes
of �nding studies, technical reports, and other publications
that could aid the search for information about active treat-
ments in the �eld. Some of the largest organizations with the
greatest reach �nancially and logistically do not includemuch
information on mental health in their reports. Organizations
and programs like UNAIDS, theWorld Health Organization,
and the US Government’s President’s Emergency Plan for
AIDS Relief (PEPFAR) oen mention mental health brie�y
and in terms of the broader psychosocial aspects without
going into psychiatric diagnoses and the options to treat them
[10, 61–65].
Some smaller organizations have been making strides
in treatment for HIV positive PWID and in reporting on
methods of treatment. For example reports from the Global
Initiative on Psychiatry are oen in-depth and discuss the
treatment options, or lack thereof, with a focus on mental
health and HIV globally, in such places as Eastern Europe
[66], Kazakhstan [67], and Tajikistan [68]. If there is to be
any progress in the integration of mental health treatment
options for HIV positive PWID, it will take a concerted effort
on the part of all organizations to include and incorporate
the screening for and treatment of mental disorders into their
activities.
Extrapolating from the existing literature on treating
comorbid substance use and nonaddictive mental disorders,
a number of recommendations can be made for meeting the
mental health needs of people who inject drugs. To the extent
possible it works best to have one-stop care where all services
are integrated within the same program and team meetings
take place with all providers present [69]. is would include
the integration of medical care for those programs that
serve HIV positive populations. Use of a shared electronic
record in this setting further enhances integration because
providers can rapidly see one another’s interventions. Mental
health services that can be provided in integrated settings
include comprehensive assessment and differential diagnosis;
medications for both psychiatric and substance use disorders;
psychotherapies, especially motivational interviewing and
cognitive behavioral therapy; psychosocial support and social
services; a thorough assessment of drug interactions and
toxicities; and a comprehensive way to monitor people with
multiple chronic relapsing disorders.
Other possibilities to achieve at least some degree of
integration of services, in descending order of the likelihood
of success, are programs colocated at the same site even
though they are not integrated, case managers who escort
patients from one service to other unrelated services, and
having clinicians in unrelated settings share information and
clinical decision making. Because buprenorphine treatment
is more realistic to provide than methadone in medical set-
tings, use of this agent for opioid substitution therapy can also
facilitate integration of services. Screening consenting clients
for common mental illnesses in methadone maintenance
programs and those that offer clean injection equipment
could help facilitate comprehensive care if such programs are
linked with and make referrals to mental health services.
Achieving integrated services will require more success-
ful strategies for funding the treatment of mental disor-
ders, especially in low and middle-income countries; new
approaches to overcoming systemic barriers to integration,
such as the tendency seen in the United States to separately
fund and operate services for addictive and nonaddictive
mental disorders [70]; and a commitment by the largest
global health care organizations to include the diagnosis
and treatment of mental disorders in HIV/AIDS and other
treatment guidelines and programming.
9. Conclusion
People who inject drugs are more likely to be HIV positive
and to have a mental disorder than the general population.
e health needs of PWID should be met not only because
it is a human right, but also to effectively combat the
global HIV epidemic. In order to address the needs of HIV
positive PWID, policy and programs must include mental
health services, which include adequate and available drug
treatment options, including opioid substitution therapy.
Addressing the mental health and substance abuse needs of
people who inject drugs will help to prevent the acquisition
and spread of HIV. Mental disorders and injection-drug use
are highly stigmatized and remain a low priority for HIV-
related funding and research. More research must be done
to understand the relationship between mental disorders,
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injection-drug use and HIV prevention, and more program-
ming addressing these three problems in a comprehensive
way needs to be developed, funded, and studied.
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